title: Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells.
abstract: It has been reported that HER2 level is strongly correlated with the expression of MMP-7 in some carcinomas. HER2 is a preferred heterodimerization partner of EGFR, HER3, and HER4. HER2 overexpression is believed to enhance the signaling from these receptors in response to binding of their specific ligands. In this study, we show that heregulin-beta (HRG-beta) stimulation remarkably induced MMP-7 promoter activity and significantly enhanced the expression and activity of MMP-7 in MCF-7 cells overexpressing HER2. The expression of c-Jun and c-Fos and the level of the phosphorylated c-Jun were markedly increased after HRG-beta treatment in MCF-7/HER2 cells. Increased MMP-7 promoter activity was observed in MCF-7/c-Jun cells. The activity of the MMP-7 promoter induced by HRG-beta in MCF-7/HER2 cells could be inhibited by a dominant negative c-Jun mutant TAM67 and by the mutagenesis of the AP-1 site. c-Jun binding to MMP-7 promoter was confirmed by ChIP assays. The data indicate a close link among HRG-beta stimulation, HER signaling, and AP-1 activation. Our data suggest that HRG-beta-induced MMP-7 expression was regulated by HER2-mediated AP-1 activation in MCF-7 cells.
authors.affiliation: Institute of Basic Medical Sciences, Beijing, 100850, People's Republic of China.
authors.forename: Guogang
authors.initials: G
authors.lastname: Yuan
authors.forename: Lu
authors.initials: L
authors.lastname: Qian
authors.forename: Lun
authors.initials: L
authors.lastname: Song
authors.forename: Ming
authors.initials: M
authors.lastname: Shi
authors.forename: Dan
authors.initials: D
authors.lastname: Li
authors.forename: Ming
authors.initials: M
authors.lastname: Yu
authors.forename: Meiru
authors.initials: M
authors.lastname: Hu
authors.forename: Beifen
authors.initials: B
authors.lastname: Shen
authors.forename: Ning
authors.initials: N
authors.lastname: Guo
mesh_terms: D001665:Binding Sites; D045744:Cell Line, Tumor; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D020783:Matrix Metalloproteinase 7 / Q000235:genetics* / Q000378:metabolism; D020890:Neuregulin-1 / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects; D011401:Promoter Regions, Genetic; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D018808:Transcription Factor AP-1 / Q000378:metabolism*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D020783:Matrix Metalloproteinase 7; D020890:Neuregulin-1; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; D018808:Transcription Factor AP-1